Registries for orphan drugs: generating evidence or marketing tools?
Published 21 October 2020 Independent disease registries for pre-and post-approval of novel treatments for rare diseases are increasingly important for healthcare professionals, patients, regulators and the pharmaceutical industry. Current registries for rare diseases to evaluate orphan drugs are mainly set up and owned by the pharmaceutical industry which leads to unacceptable conflicts of intere
https://www.lupop.lu.se/article/registries-orphan-drugs-generating-evidence-or-marketing-tools - 2025-05-05